In recent decades, novel sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i) became the new pillar of treatment for people with type 2 diabetes mellitus (T2DM) and proteinuric CKD, since more and more studies demonstrated the nephroprotective and antiproteinuric effect of these drugs [17,18,19,20,21]. Here, SLC5A2 is linked to type 2 diabetes mellitus.